Bio-Techne Corp $TECH Holdings Cut by Summit Creek Advisors LLC

Posted by Francis Steltz on May 21st, 2026

Summit Creek Advisors LLC decreased its position in shares of Bio-Techne Corp (NASDAQ:TECH – Free Report) by 7.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 282,580 shares of the biotechnology company’s stock after selling 21,145 shares during the period. Bio-Techne comprises approximately 2.6% of Summit Creek Advisors LLC’s holdings, making the stock its 8th biggest holding. Summit Creek Advisors LLC owned about 0.18% of Bio-Techne worth $16,619,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TECH. Danske Bank A S purchased a new stake in Bio-Techne during the 4th quarter worth $29,000. eCIO Inc. purchased a new stake in Bio-Techne during the 4th quarter worth $30,000. Measured Wealth Private Client Group LLC purchased a new stake in Bio-Techne during the 3rd quarter worth $32,000. iSAM Funds UK Ltd purchased a new stake in Bio-Techne during the 3rd quarter worth $33,000. Finally, EverSource Wealth Advisors LLC increased its stake in Bio-Techne by 506.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock worth $35,000 after buying an additional 562 shares during the period. Hedge funds and other institutional investors own 98.95% of the company’s stock.

Bio-Techne Trading Up 2.7%

NASDAQ TECH opened at $46.70 on Thursday. Bio-Techne Corp has a one year low of $43.19 and a one year high of $72.16. The company has a 50-day simple moving average of $52.42 and a 200-day simple moving average of $58.41. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.18 and a current ratio of 4.49. The firm has a market capitalization of $7.31 billion, a PE ratio of 67.68, a price-to-earnings-growth ratio of 3.54 and a beta of 1.41.

Bio-Techne (NASDAQ:TECH – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.02). Bio-Techne had a net margin of 9.05% and a return on equity of 13.57%. The business had revenue of $311.42 million during the quarter, compared to analyst estimates of $316.11 million. During the same period last year, the firm posted $0.56 earnings per share. The company’s quarterly revenue was down 1.5% on a year-over-year basis. On average, equities analysts forecast that Bio-Techne Corp will post 1.69 earnings per share for the current year.

Bio-Techne Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Monday, May 18th will be issued a $0.08 dividend. The ex-dividend date of this dividend is Monday, May 18th. This represents a $0.32 annualized dividend and a dividend yield of 0.7%. Bio-Techne’s payout ratio is 46.38%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TECH. UBS Group reaffirmed a “buy” rating and set a $79.00 price target (up from $70.00) on shares of Bio-Techne in a research note on Thursday, February 5th. Royal Bank Of Canada set a $62.00 price target on shares of Bio-Techne and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Zacks Research raised shares of Bio-Techne from a “strong sell” rating to a “hold” rating in a research note on Monday, February 9th. Weiss Ratings raised shares of Bio-Techne from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Bio-Techne in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $65.92.

Get Our Latest Research Report on TECH

Bio-Techne Company Profile

(Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.